Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
$139.56
$0.29(0.21%)
At close: 4:00 PM EST
$139.56
$0.29(0.21%)
Day’s Range― - ―
52-Week Range$84.23 - $160.18
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.01M
Market Cap
$13.91B
Enterprise Value$14.00B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$428.40M
Price to Earnings (P/E)33.3
Beta0.60
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.48
Shares Outstanding99,705,696
10 Day Avg. Volume970,629
30 Day Avg. Volume1,008,233
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)5.29
Price to Sales (P/S)5.82
P/FCF Ratio24.60
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit5.31
Enterprise Value/Ebitda21.04
Forecast
1Y Price Target
$185.13Price Target Upside32.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationAnalyst highlights that Ingrezza achieves greater than ninety percent VMAT2 target occupancy with multiple doses, indicating substantially higher potency than competing therapy and supporting premium positioning in movement disorder treatment.
Commercial Execution And Cash FlowAnalyst notes robust cash flows from Ingrezza and Crenessity and planned sales force expansion that should support commercial growth and long-term revenue diversification.
Pipeline InnovationAnalyst views late-stage programs including osavampator and direclidine plus the novel CRF2 agonist NBIP-2118 as de-risked, with potential best-in-class profiles that could expand the company's addressable markets into psychiatry and obesity.
Bears Say
Catalyst Dependence And Execution RiskAnalyst warns that near-term stock upside depends heavily on execution of Ingrezza and Crenessity commercialization, and that a year with fewer clinical catalysts could limit material share price appreciation without positive pipeline readouts.
Clinical Trial SetbackAnalyst reports the Phase III study of valbenazine in dyskinetic cerebral palsy failed to meet primary and key secondary endpoints, reducing confidence in that label expansion opportunity.
Pipeline Valuation PressureAnalyst indicates the net pipeline reduces per-share valuation, reflecting potential disappointments or lower-than-expected returns from development programs.
Neurocrine News
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $160.18 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $13.91B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is May 06, 2026 which is in 83 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 11, 2026. The company reported $1.48 earnings per share for the quarter, missing the consensus estimate of $1.804 by -$0.324.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,705,696 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.48 in its last earnings report, missing expectations of $1.804. Following the earnings report the stock price went down -6.351%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$185.13 (32.65% Upside)
$185.13 (32.65% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 403.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.81%
12-Months-Change
Fundamentals
Return on Equity
14.96%
Trailing 12-Months
Asset Growth
20.67%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX Company Deck
NBIX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful product launches, particularly with CRENESSITY and INGREZZA, alongside robust pipeline development. However, there are notable challenges such as the failure of the valbenazine study to meet its primary endpoint and pricing pressures on INGREZZA. Despite these challenges, the overall sentiment reflects confidence in continued growth and strategic investments.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$185.13
▲(32.65% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.10% Insiders
28.88% Mutual Funds
0.29% Other Institutional Investors
42.89% Public Companies and Individual Investors